What is the recommended treatment for hyperkeratosis?

Treatment for Hyperkeratosis

Topical keratolytics represent first-line treatment for hyperkeratosis, with urea (10-40%) being the most frequently used agent, applied once or twice daily to reduce scales and thickened skin 1.

Topical Treatment Approach

First-Line Keratolytic Agents

The superiority of keratolytics over simple emollients has been demonstrated for removing hyperkeratosis 1. The following agents have proven efficacy:

• Urea (≥10%): Most commonly used in clinical practice; concentration can be increased up to 20%, or even 40% in localized areas of thick hyperkeratosis 1
• Alpha-hydroxyacids (5-12%): Including lactic acid 1, 2
• Salicylic acid (>2%): Effective alone or in combination 1, 2
• Propylene glycol (>20%) 1

These can be used alone or in combination, applied once or twice daily and tapered based on response 1.

Important Application Caveats

Avoid applying keratolytics to the face, flexures, and areas of fissuring, as they may induce irritation, itching, or burning 1. For children under age 1 year, urea (≥10%) is not recommended except once daily on limited areas like palms and soles 1.

Adjunctive Topical Measures

• Emollients: Apply at least twice daily, ideally after bathing, to all affected areas for skin hydration 1
• Bathing regimen: Daily lukewarm baths (30+ minutes) with gentle scale removal using sponges or microfiber cloths; add moisturizing additives, baking soda (3-6 g/L), or saline 1
• Topical retinoids: Tazarotene has demonstrated efficacy in small studies for severe hyperkeratosis 1

Systemic Treatment for Severe Cases

When to Consider Systemic Therapy

Systemic retinoids should be considered when topical therapies are insufficiently effective or when patients need respite from excessive topical treatment 1.

Acitretin: The Preferred Systemic Agent

Acitretin is the drug of choice for severe hyperkeratosis, particularly in conditions like congenital ichthyoses with thick scales 1, 3. It is the only retinoid approved by the European Medical Agency for treating congenital ichthyoses 1.

Dosing Strategy:

• Start low: 10 mg daily for adults (or every second day) 1
• Most patients require ≤0.5 mg/kg/day; maintenance often achievable with 10-25 mg/day 1
• Maximum approved dose: 75 mg/day 1
• Gradually increase after a few weeks until sufficient improvement with tolerable side-effects 1
• Avoid rapid dose escalation to minimize side-effects and maintain patient compliance 1

Special Considerations:

• Patients with marked erythroderma may need only low doses (<25-30 mg/day in adults) to avoid skin irritation, fragility, or blistering 1
• Hyperkeratotic palmoplantar conditions respond well to acitretin as monotherapy or combined with other modalities 4, 3

Alternative Systemic Retinoids

Other retinoids (isotretinoin, alitretinoin) can be considered but acitretin remains the primary choice based on efficacy data 1.

Combination Approaches for Refractory Cases

For hyperkeratotic conditions resistant to monotherapy:

• Acitretin + phototherapy (UVB or PUVA): More efficacious than either alone, allows lower doses of each modality 4, 3
• Acitretin + topical calcipotriol: Has shown additive benefits in some hyperkeratotic conditions 3, 5
• High-potency topical corticosteroids: For inflammatory hyperkeratosis (e.g., clobetasol propionate 0.05%) 6, 7

Physical Debridement

Regular physical debridement by podiatrists is recommended for palmoplantar hyperkeratosis, particularly in conditions like epidermolysis bullosa where hyperkeratosis can lead to painful fissures 8. This should be combined with keratolytic therapy for optimal results.

Treatment Algorithm Summary

1. Mild-to-moderate hyperkeratosis: Start with topical urea 10-20% twice daily + emollients
2. Localized thick areas: Increase urea to 40% or add salicylic acid 5-10%
3. Inadequate response after 4-8 weeks: Add topical retinoid (tazarotene) or consider physical debridement
4. Severe or widespread hyperkeratosis: Initiate acitretin 10 mg daily, titrate slowly based on response
5. Refractory cases: Combine acitretin with phototherapy or topical calcipotriol

The key to successful management is balancing efficacy with tolerability, as patient compliance is essential for long-term control 1.